<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537013</url>
  </required_header>
  <id_info>
    <org_study_id>13575-237</org_study_id>
    <nct_id>NCT04537013</nct_id>
  </id_info>
  <brief_title>Clinical Study of Chondro-Gide® for Large Chondral Lesions in the Knee</brief_title>
  <acronym>SECURE</acronym>
  <official_title>A ProSpective, MulticEnter, Concurrently Controlled Clinical Study of Chondro-Gide® ArticUlar Cartilage CoveR for the Treatment of Large Chondral Lesions in the KnEe (SECURE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geistlich Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Telos Partners</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Geistlich Pharma AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, prospective, concurrently controlled, non-randomized, double-blind (patient and&#xD;
      assessor). Treatment of large chondral lesions in the knee with microfracture plus the&#xD;
      Chondro-Gide® ACC is non-inferior to treatment of small chondral lesions treated with&#xD;
      microfracture alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study evaluates the investigational treatment for treating large chondral lesions of the&#xD;
      knee to the control treatment of microfracture alone for treating small lesions.Eligible&#xD;
      patients with a large lesion will be treated with microfracture plus the Chondro-Gide® ACC&#xD;
      and compared to patients with small lesions that are treated with microfracture alone.&#xD;
      Outcome measures to be assessed include patient reported outcomes and freedom from certain&#xD;
      adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2020</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients achieving composite clinical success (CCS) at 24 months follow-up, with CCS</measure>
    <time_frame>24 Months</time_frame>
    <description>The CCS is defined as a patient meeting all of the three following criteria:&#xD;
Improvement in the Pain sub-scale of the Knee Injury and Osteoarthritis Outcomes Score (KOOS) between baseline to 24 months follow-up&#xD;
Improvement in function, defined as an improvement in the International Knee Documentation Committee (IKDC) score between baseline to 24 months follow-up&#xD;
Freedom from device- or procedure-related serious adverse events (SAEs) or secondary surgical intervention related to the device, procedure, or treated lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee Injury and Osteoarthritis Outcome Score</measure>
    <time_frame>Baseline, 6 weeks, 3 months, 6 months, 12 months, 18 months, and 24 months</time_frame>
    <description>The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a knee-specific instrument, developed to assess the patients' opinion about their knee and associated problems. The KOOS evaluates both short-term and long-term consequences of knee injury. Calculate the mean score of the individual items of each subscale and divide by 4 (the highest possible score for a single answer option). Traditionally in orthopedics, 100 indicates no problems and 0 indicates extreme problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Observation of Cartilage Score</measure>
    <time_frame>3 months, 12 months, and 24 months</time_frame>
    <description>Magnetic Resonance Image (MRI) will be obtain during the course of the study at 3 months, 12 months, and 24 months. MOCART 2.0 scoring will occur by independent assessment using the MOCART score. The score is a 9-part and 29-item scoring system, also resulting in a final cartilage repair tissue score between 0 and 100 points; 0 points represent the worst imaginable score, 100 points represent the best imaginable score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>6 weeks, 3 months, 6 months, 12 months, 18 months, and 24 months</time_frame>
    <description>Were you satisfied with the procedure? (Satisfied, Somewhat satisfied, Neutral, Somewhat unsatisfied, Unsatisfied)&#xD;
Would you have this procedure again if needed on the other knee? (Definitely yes, Probably yes, Not Sure, Probably Not, Definitely Not)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tegner Activity Scale</measure>
    <time_frame>6 weeks, 3 months, 6 months, 12 months, 18 months, and 24 months</time_frame>
    <description>The Tegner activity score is a one-item score that grades activity based on work and sports activities. Tegner activity level scale is a scale that aims to provide a standardized method of grading work and sporting activities. A scale of the highest level activity being 10 and the lowest being 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Employment status</measure>
    <time_frame>Baseline, 6 weeks, 3 months, 6 months, 12 months, 18 months, and 24 months</time_frame>
    <description>Employment status will be collected as: Employed full-time, Employed part-time, Not employed due to knee problems, Not employed due to reasons other than knee problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol-5 Dimension (EQ-5D)</measure>
    <time_frame>Baseline, 6 weeks, 3 months, 6 months, 12 months, 18 months, and 24 months</time_frame>
    <description>The EQ-5D measures as a descriptive system comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Knee Injuries</condition>
  <condition>Cartilage Injury</condition>
  <condition>Cartilage Disease</condition>
  <condition>Knee Discomfort</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with small chondral lesions of the knee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with large chondral lesions of the knee</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microfracture</intervention_name>
    <description>Debridement of cartilage followed by placement of small holes in the effected area to fill the debrided area with marrow and cells.</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microfracture plus placement of Chondro-Gide® ACC</intervention_name>
    <description>Debridement of cartilage followed by placement of small holes in the effected area to fill the debrided area with marrow and cells, followed by affixing Chondro-Gide® with fibrin glue.</description>
    <arm_group_label>Investigational Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent&#xD;
&#xD;
          2. One symptomatic knee with cartilage defect on the medial femoral condyle, lateral&#xD;
             femoral condyle, or trochlea, identified MRI or arthroscopy&#xD;
&#xD;
          3. Between 18 and 55 years of age&#xD;
&#xD;
          4. Subject is willing and able to comply with all study procedures, including visits,&#xD;
             diagnostic procedures, and the rehabilitation protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. BMI ≥ 30 kg/m2&#xD;
&#xD;
          2. Symptomatic contralateral knee&#xD;
&#xD;
          3. Diagnosis of radiographic osteoarthritis with Kellgren-Lawrence grade 3 or more&#xD;
&#xD;
          4. Prior surgical treatment of the cartilage using microfracture, mosaicplasty, or&#xD;
             autologous chondrocyte implantation (debridement and lavage are acceptable if the&#xD;
             procedure was at least 3 months prior to enrollment)&#xD;
&#xD;
          5. Patella dysplasia&#xD;
&#xD;
          6. Chronic inflammatory arthritis or infectious arthritis&#xD;
&#xD;
          7. History of autoimmune disease or immunodeficiency&#xD;
&#xD;
          8. History of connective tissue disease&#xD;
&#xD;
          9. Intra-articular steroid use within the 3 months prior to enrollment&#xD;
&#xD;
         10. Other intra-articular injections (e.g. hyaluronic acid) within 3 months prior to&#xD;
             enrollment&#xD;
&#xD;
         11. The patient is currently being treated with radiation, chemotherapy, immunosuppression&#xD;
             or systemic steroid therapy with a dose equivalent to more than 5 mg prednisolone&#xD;
&#xD;
         12. Pregnancy or lack of adequate contraceptives if a female of child-bearing potential&#xD;
&#xD;
         13. Enrolled in another study, involved in the study (as a&#xD;
             researcher/investigator/sponsor), or relative of someone directly involved in the&#xD;
             study&#xD;
&#xD;
         14. Active infection of the index knee&#xD;
&#xD;
         15. Previous diagnosis of osteoporosis as diagnosed by DEXA, bone densitometry or CT scan&#xD;
&#xD;
         16. Any disorder or impairment that would interfere with evaluation of outcomes measures,&#xD;
             such as neurological, degenerative muscular, psychiatric, or cognitive conditions&#xD;
&#xD;
         17. History or current substance or alcohol abuse as defined by the DSM-V&#xD;
&#xD;
         18. Any other medical condition that the investigator determines would interfere with the&#xD;
             validity of the study&#xD;
&#xD;
         19. Known allergy to porcine collagen&#xD;
&#xD;
         20. Symptom duration greater than 36 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Despoina Natsiou Schmiady, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Geistlich Pharma AG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Plancher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Plancher Orthopedics and Sports Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rena Mandino</last_name>
    <phone>352 3593581</phone>
    <email>rmandino@telospartnersllc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patrick Reischling, MA</last_name>
    <phone>720-879-7828</phone>
    <email>preischling@telospartnersllc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The CORE Institute</name>
      <address>
        <city>Sun City West</city>
        <state>Arizona</state>
        <zip>85080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyse Williams</last_name>
      <phone>623-241-8639</phone>
      <email>alyse.williams@more-foundation.org</email>
    </contact>
    <contact_backup>
      <last_name>Debra Sietsema</last_name>
      <email>debra.sietsema@more-foundation.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Rose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CORE Orthopaedic Medical Center</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farouk Awad</last_name>
      <phone>760-943-6700</phone>
      <phone_ext>162</phone_ext>
      <email>fawad@coreorthopaedic.com</email>
    </contact>
    <investigator>
      <last_name>Gregory Loren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Johns Creek</city>
        <state>Georgia</state>
        <zip>30097</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lavanya Veda</last_name>
      <phone>404-778-6608</phone>
      <email>lavanya.vedanarayanan@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Pombo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Orthopaedics Institute</name>
      <address>
        <city>Timonium</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawanna Jackson</last_name>
      <phone>301-832-5960</phone>
      <email>Shawanna.D.Jackson@medstar.net</email>
    </contact>
    <contact_backup>
      <last_name>Flossine Brown</last_name>
      <phone>(301)832-5960</phone>
      <email>flossine.brown@medstar.net</email>
    </contact_backup>
    <investigator>
      <last_name>James Dreese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Plancher Orthopedics and Sports Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Petterson, MPT, PhD</last_name>
      <phone>203-869-2002</phone>
      <phone_ext>14</phone_ext>
      <email>spetterson@ofals.org</email>
    </contact>
    <investigator>
      <last_name>Kevin Plancher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Camp Hill Veteran's Memorial Lane</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara Sparavalo</last_name>
      <email>sara@drivanwong.com</email>
    </contact>
    <investigator>
      <last_name>Ivan Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Breanne Flood</last_name>
      <phone>(289) 237-7380</phone>
      <email>bflood@stjosham.on.ca</email>
    </contact>
    <investigator>
      <last_name>Moin Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martin Luther Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <zip>14139</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Hofschulz</last_name>
      <email>Kerstin.Hofschulz@jsd.de</email>
    </contact>
    <investigator>
      <last_name>Wolf Petersen, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig Holstein Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffen Herzmann</last_name>
      <email>Steffen.Herzmann@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Unger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominik Vogt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sportklinik Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nils Frier</last_name>
      <email>freier@flyingstudyteam.com</email>
    </contact>
    <investigator>
      <last_name>Martin Volz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manju Ganesh-Kumar</last_name>
      <email>manju.ganesh-kumar@ukr.de</email>
    </contact>
    <investigator>
      <last_name>Peter Angele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microfracture</keyword>
  <keyword>Cartilage</keyword>
  <keyword>Knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cartilage Diseases</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Knee Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

